BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29684201)

  • 21. [Clinical and pathological features of 13 children with Epstein-Barr virus-positive lymphoproliferative disease].
    Chen TM; Deng ZJ; Hu B; Hu HL; Chen HY; Li SY; Liu G
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):759-764. PubMed ID: 30293280
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.
    Abolhassani H; Edwards ES; Ikinciogullari A; Jing H; Borte S; Buggert M; Du L; Matsuda-Lennikov M; Romano R; Caridha R; Bade S; Zhang Y; Frederiksen J; Fang M; Bal SK; Haskologlu S; Dogu F; Tacyildiz N; Matthews HF; McElwee JJ; Gostick E; Price DA; Palendira U; Aghamohammadi A; Boisson B; Rezaei N; Karlsson AC; Lenardo MJ; Casanova JL; Hammarström L; Tangye SG; Su HC; Pan-Hammarström Q
    J Exp Med; 2017 Jan; 214(1):91-106. PubMed ID: 28011864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity.
    Picard C; Dogniaux S; Chemin K; Maciorowski Z; Lim A; Mazerolles F; Rieux-Laucat F; Stolzenberg MC; Debre M; Magny JP; Le Deist F; Fischer A; Hivroz C
    Eur J Immunol; 2009 Jul; 39(7):1966-76. PubMed ID: 19548248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.
    Chan AY; Punwani D; Kadlecek TA; Cowan MJ; Olson JL; Mathes EF; Sunderam U; Fu SM; Srinivasan R; Kuriyan J; Brenner SE; Weiss A; Puck JM
    J Exp Med; 2016 Feb; 213(2):155-65. PubMed ID: 26783323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
    Patton JT; Lustberg ME; Lozanski G; Garman SL; Towns WH; Drohan CM; Lehman A; Zhang X; Bolon B; Pan L; Kinghorn AD; Grever MR; Lucas DM; Baiocchi RA
    Oncotarget; 2015 Feb; 6(5):2693-708. PubMed ID: 25393910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.
    Park S; Ko YH
    J Dermatol; 2014 Jan; 41(1):29-39. PubMed ID: 24438142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EBV in T-/NK-Cell Tumorigenesis.
    Kimura H
    Adv Exp Med Biol; 2018; 1045():459-475. PubMed ID: 29896680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.
    Ohshima K; Kimura H; Yoshino T; Kim CW; Ko YH; Lee SS; Peh SC; Chan JK;
    Pathol Int; 2008 Apr; 58(4):209-17. PubMed ID: 18324913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation.
    Moshous D; Martin E; Carpentier W; Lim A; Callebaut I; Canioni D; Hauck F; Majewski J; Schwartzentruber J; Nitschke P; Sirvent N; Frange P; Picard C; Blanche S; Revy P; Fischer A; Latour S; Jabado N; de Villartay JP
    J Allergy Clin Immunol; 2013 Jun; 131(6):1594-603. PubMed ID: 23522482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency.
    Alkhairy OK; Perez-Becker R; Driessen GJ; Abolhassani H; van Montfrans J; Borte S; Choo S; Wang N; Tesselaar K; Fang M; Bienemann K; Boztug K; Daneva A; Mechinaud F; Wiesel T; Becker C; Dückers G; Siepermann K; van Zelm MC; Rezaei N; van der Burg M; Aghamohammadi A; Seidel MG; Niehues T; Hammarström L
    J Allergy Clin Immunol; 2015 Sep; 136(3):703-712.e10. PubMed ID: 25843314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr Virus-positive T-cell Lymphoproliferative Disease Following Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia.
    Yui S; Yamaguchi H; Imadome K; Arai A; Takahashi M; Ohashi R; Tamai H; Moriya K; Nakayama K; Shimizu A; Inokuchi K
    J Nippon Med Sch; 2016; 83(1):35-42. PubMed ID: 26960588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome.
    Chen G; Chen L; Qin X; Huang Z; Xie X; Li G; Xu B
    Int J Clin Exp Pathol; 2014; 7(10):7110-3. PubMed ID: 25400806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expression of NK cell receptors in Epstein-Barr virus-positive gammadelta T-cell lymphoproliferative disorders.
    Zhang Y; Ohyashiki JH; Shimizu N; Ohyashiki K
    Hematology; 2010 Feb; 15(1):43-7. PubMed ID: 20132662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect.
    Sawada A; Sato E; Koyama M; Higuchi B; Kusuki S; Kim JY; Takeshita Y; Sakata A; Sakata N; Okamura T; Yasui M; Inoue M; Kawa K
    Am J Hematol; 2006 Aug; 81(8):576-81. PubMed ID: 16823820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
    Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
    J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
    Baiocchi RA; Caligiuri MA
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.
    Petrova M; Muhtarova M; Nikolova M; Magaev S; Taskov H; Nikolovska D; Krastev Z
    World J Gastroenterol; 2006 Sep; 12(35):5711-6. PubMed ID: 17007027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathologic features of systemic EBV-positive T/NK-cell lymphoproliferative disease in adults].
    Zheng XD; Zhou XG; Jin Y; Xie JL; Wei XJ; Chen SY; Mei X; Gong LP; Lü BB
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):227-34. PubMed ID: 21615995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.